<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Acid plays a significant role in the development of <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux</z:e> symptoms and tissue damage </plain></SENT>
<SENT sid="1" pm="."><plain>It is generally assumed that acid suppressive therapy with <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> improves or eliminates symptoms of <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> by normalizing intra-oesophageal pH </plain></SENT>
<SENT sid="2" pm="."><plain>However, the degree of acid suppression induced by <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> therapy in patients with <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> and/or <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> has not been adequately studied </plain></SENT>
<SENT sid="3" pm="."><plain>AIM: To assess the efficacy of <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> in normalizing intra-oesophageal and intra-gastric pH in patients with <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> with and without <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> who have been rendered symptom-free by acid-suppressive therapy </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Patients with <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> and <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> were prospectively evaluated by dual sensor 24-h pH monitoring while receiving <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> therapy for complete control of <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> symptoms </plain></SENT>
<SENT sid="5" pm="."><plain>Analyses and comparisons of intra-oesophageal and intra-gastric pH profiles on therapy were then made </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: One hundred and ten patients, 98 men and 12 women, with <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> (n = 62) and/or <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (n = 48), were studied </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> tolerated <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> well and were asymptomatic at the time of the study </plain></SENT>
<SENT sid="8" pm="."><plain>Thirty-six (58%) patients with <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> and 24 (50%) patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (P = 0.4) normalized their intra-oesophageal pH profiles on <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Compared with patients with <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e>, patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> were more likely to have higher degree of pathologic <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> despite <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> therapy (DeMeester score 50.5 +/- 8.2 vs. 31.4 +/- 4.6, P = 0.03) and exhibited less intra-gastric acid suppression (% total pH &lt; 4.0: 53.9 +/- 2.7 vs. 39.9 +/- 2.6, P = 0.0004), particularly supine (% pH &lt; 4.0: 62.1 +/- 3.4 vs. 44.8 +/- 3.4, P = 0.0006) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">Gastro-oesophageal reflux disease</z:e> patients with or without <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> continue to exhibit pathologic <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> and low intra-gastric pH despite <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> therapy that accomplishes complete reflux symptom control </plain></SENT>
<SENT sid="11" pm="."><plain>Further, intra-oesophageal and intra-gastric pH control is significantly more difficult to achieve in patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>These findings may have significant therapeutic implications </plain></SENT>
</text></document>